Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Immunology | Hematology
 Disease Category: Non-Hodgkin's Lymphoma
Location: United States, CA

Trial Information

SWOG S0806: A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) In Combination with Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL)

You have been asked to participate in this research study because you have newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL). This experimental study is being done to test the best dose and safety for using vorinostat (SAHA) together with rituximab-CHOP. It is also being done to see if research participants treated with the vorinostat-R-CHOP chemotherapy will have longer remissions than expected in patients treated with R-CHOP chemotherapy alone. It will take you about 6 months to finish the vorinostat-rituximab-CHOP treatments. You will return to your study doctor around Week 26 for tests and scans. You will then return for a follow-up visit to your study doctor every 6 months for two years and then once a year after that for a maximum of 5 years (from the time you registered on the study). Your study doctor may wish to see you more often. The follow-up evaluation tests that are standard of cancer care will include a medical history, physical examination, and scans to see whether your cancer has become worse.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.